Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Quick Listen: Scrip’s Five Must-Know Things

Corporate Pandemic Impact, Important US Launches And RSV Overview

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 7 August 2020.

Making headlines this time are the corporate impact of the coronavirus pandemic, new launches for depression and lymphoma in the US and an overview of progress in the RSV space.

Stories mentioned in this episode:

(Also see "Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales" - Scrip, 31 Jul, 2020.)

(Also see "Bayer Q2 Pharma Sales Ravaged By COVID-19" - Scrip, 4 Aug, 2020.)

(Also see "US FDA Opens Door For J&J's Spravato To Another MDD Population" - Scrip, 3 Aug, 2020.)

(Also see "Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL" - Scrip, 4 Aug, 2020.)

(Also see "Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus" - Scrip, 7 Aug, 2020.)


Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts